Literature DB >> 19288476

Anti-inflammatory properties of cryptolepine.

Olumayokun A Olajide1, Abayomi M Ajayi, Colin W Wright.   

Abstract

Cryptolepine is the major alkaloid of the West African shrub, Cryptolepis sanguinolenta. Cryptolepine has been shown to inhibit nitric oxide production, and DNA binding of Nuclear Factor-kappa B following inflammatory stimuli in vitro. In order to validate the anti-inflammatory property of this compound in vivo, we investigated its effects on a number of animal models of inflammation. Cryptolepine (10-40 mg/kg i.p.) produced significant dose-dependent inhibition of the carrageenan-induced rat paw oedema, and carrageenan-induced pleurisy in rats. These effects were compared with those of the non-steroidal anti-inflammatory drug indomethacin (10 mg/kg). At doses of 10-40 mg/kg i.p., cryptolepine inhibited lipopolysaccharide (LPS)-induced microvascular permeability in mice in a dose-related fashion. Oral administration of up to 40 mg/kg of the compound for four consecutive days did not induce gastric lesion formation in rats. Analgesic activity was also exhibited by cryptolepine through a dose-related (10-40 mg/kg i.p.) inhibition of writhing induced by i.p. administration of acetic acid in mice. The results of this study reveal that cryptolepine possesses in vivo anti-inflammatory activity. (c) 2009 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19288476     DOI: 10.1002/ptr.2794

Source DB:  PubMed          Journal:  Phytother Res        ISSN: 0951-418X            Impact factor:   5.878


  15 in total

1.  Synergistic anti-malarial action of cryptolepine and artemisinins.

Authors:  Arnold D Forkuo; Charles Ansah; Kwesi M Boadu; Johnson N Boampong; Elvis O Ameyaw; Ben A Gyan; Andrea T Arku; Michael F Ofori
Journal:  Malar J       Date:  2016-02-16       Impact factor: 2.979

2.  Design and in vitro haemolytic evaluation of cryptolepine hydrochloride-loaded gelatine nanoparticles as a novel approach for the treatment of malaria.

Authors:  Noble Kuntworbe; Raida Al-Kassas
Journal:  AAPS PharmSciTech       Date:  2012-04-05       Impact factor: 3.246

Review 3.  A review of the anticancer potential of the antimalarial herbal cryptolepis sanguinolenta and its major alkaloid cryptolepine.

Authors:  C Ansah; K B Mensah
Journal:  Ghana Med J       Date:  2013-09

4.  Anti-inflammatory, Anti-nociceptive and Total polyphenolic Content of Hydroethanolic Extract of Ocimum gratissimum L. Leaves.

Authors:  A M Ajayi; J K Tanayen; Joc Ezeonwumelu; S Dare; A Okwanachi; B Adzu; O G Ademowo
Journal:  Afr J Med Med Sci       Date:  2014-09

5.  Recent Advances in the Chemistry and Pharmacology of Cryptolepine.

Authors:  Steven D Shnyder; Colin W Wright
Journal:  Prog Chem Org Nat Prod       Date:  2021

6.  Antifertility activity of Cryptolepis sanguinolenta leaf ethanolic extract in male rats.

Authors:  Ayodeji F Ajayi; Roland E Akhigbe
Journal:  J Hum Reprod Sci       Date:  2012-01

7.  Cryptolepine inhibits hepatocellular carcinoma growth through inhibiting interleukin-6/STAT3 signalling.

Authors:  Seth A Domfeh; Patrick W Narkwa; Osbourne Quaye; Kwadwo A Kusi; Gordon A Awandare; Charles Ansah; Alimatu Salam; Mohamed Mutocheluh
Journal:  BMC Complement Med Ther       Date:  2021-06-02

8.  Inhibition of Neuroinflammation in LPS-Activated Microglia by Cryptolepine.

Authors:  Olumayokun A Olajide; Harsharan S Bhatia; Antonio C P de Oliveira; Colin W Wright; Bernd L Fiebich
Journal:  Evid Based Complement Alternat Med       Date:  2013-05-08       Impact factor: 2.629

Review 9.  Phytochemical and Pharmacological Review of Cryptolepis sanguinolenta (Lindl.) Schlechter.

Authors:  Newman Osafo; Kwesi Boadu Mensah; Oduro Kofi Yeboah
Journal:  Adv Pharmacol Sci       Date:  2017-10-15

10.  Isobolographic analysis of co-administration of two plant-derived antiplasmodial drug candidates, cryptolepine and xylopic acid, in Plasmodium berghei.

Authors:  Elvis O Ameyaw; Kodwo B Asmah; Robert P Biney; Isaac T Henneh; Phyllis Owusu-Agyei; James Prah; Arnold D Forkuo
Journal:  Malar J       Date:  2018-04-04       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.